Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADARx Pharmaceuticals, Inc.ADRX · Entity 183937 | Director | September 24, 2026 | September 24, 2026 |
| Legend Biotech CorpLEGN · Entity 4033 | Director · Chief Executive Officer | June 30, 2026 | July 02, 2026 |
| TCGX Acquisition Corp.TCGX · Entity 6504 | Director | August 04, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADARx Pharmaceuticals, Inc.
Report date September 24, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.69 · Expires 2036-07-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-24 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Granted to the Reporting Person on July 20, 2026. 1/4 of the total number of shares vest and become exercisable on July 20, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted to the Reporting Person on July 20, 2026. 1/4 of the total number of shares vest and become exercisable on July 20, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Legend Biotech Corp
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 238,490 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Gift · Disposed 3,382 · Balance 238,490 F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2: Represents a bone fide gift to a charitable organization. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
F2: Represents a bone fide gift to a charitable organization.
TCGX Acquisition Corp.
Report date August 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Legend Biotech Corp LEGN · Entity 4033 | GiftOrdinary Shares | 3,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001967360-26-000008 · form4-07022026_040714.xml · nonDerivative · entry 1 Huang Ying · CIK 0001967360 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,490 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2 · kind: Represents a bone fide gift to a charitable organization. Read SEC document |
| June 25, 2026 Filed Jun 30, 2026 01:53 UTC | Legend Biotech Corp LEGN · Entity 4033 | SaleOrdinary Shares | 5,566 | $14.78 | $82,265.48 |
DisclosureSEC source: 0001967360-26-000006 · form4-06302026_010610.xml · nonDerivative · entry 1 Huang Ying · CIK 0001967360 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,872 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2 · kind: Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units. F3 · price: The price reported in Column 4 is a weighted average price and represents the converted sales price of the ADSs of $29.56. The prices sold ranged from $28.13 to $29.98 per ADS (which is equivalent to $14.065 to $14.99 per ordinary share). The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:25 UTC | Legend Biotech Corp LEGN · Entity 4033 | SaleOrdinary Shares | 9,936 | $8.77 | $87,138.72 |
DisclosureSEC source: 0001967360-26-000004 · form4-03272026_080347.xml · nonDerivative · entry 1 Huang Ying · CIK 0001967360 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,438 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2 · kind: Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units. F3 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $17.26 to $17.82 per ADS (which is equivalent to $8.63 to $8.91 per ordinary share). The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.